VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Sanofi Aventis: Dupixent Gains New Indication Approval and Rare Disease Drug Shows Positive Phase 3 Results
Sanofi Aventis: Dupixent Gains New Indication Approval and Rare Disease Drug Shows Positive Phase 3 Results
May 24, 2026 05:21 CST Updated 06:08
Share:
